NewAmsterdam Pharma Company NV (NAMS)
NASDAQ
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibit... NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Show more
Ask ADVFN Intelligence (AI)
NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
NAARDEN, the Netherlands and MIAMI, Oct. 04, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
NAARDEN, the Netherlands and MIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical...
NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
-- Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with HeFH; achieved primary endpoint of LS mean reduction in LDL-C versus placebo, as well...
NAARDEN, The Netherlands and MIAMI, Aug. 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p<0.0001), which was...
NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.1 | -5.75013068479 | 19.13 | 19.17 | 16.51 | 342226 | 17.77947043 | CS |
| 4 | 0.38 | 2.15297450425 | 17.65 | 19.93 | 16.51 | 239438 | 18.4181485 | CS |
| 12 | 0.86 | 5.00873616773 | 17.17 | 19.93 | 15.19 | 311979 | 16.97283922 | CS |
| 26 | -3.97 | -18.0454545455 | 22 | 22.72 | 15.19 | 270493 | 17.68057944 | CS |
| 52 | 7.73 | 75.0485436893 | 10.3 | 26.35 | 8.64 | 229399 | 18.1904567 | CS |
| 156 | 7.03 | 63.9090909091 | 11 | 32.88 | 5.6326 | 155412 | 16.37677933 | CS |
| 260 | 7.03 | 63.9090909091 | 11 | 32.88 | 5.6326 | 155412 | 16.37677933 | CS |
Monksdream
7 months ago
makinezmoney
2 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
